These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Evaluation of the quality of life and sexual functioning of women using a 30-microg ethinyloestradiol and 3-mg drospirenone combined oral contraceptive.
    Author: Skrzypulec V, Drosdzol A.
    Journal: Eur J Contracept Reprod Health Care; 2008 Mar; 13(1):49-57. PubMed ID: 18283600.
    Abstract:
    OBJECTIVES: To evaluate the effect of a 30-microg ethinyloestradiol and 3-microg drospirenone (EE 30 microg/drsp 3 mg) combined oral contraceptive (COC) on the quality of life (QoL) and sexual functioning. METHODS: Sixty-one women using this COC were assessed. The control group consisted of 65 women using different types of COC. A questionnaire with a Polish version of the Short Form-36 Health Survey (SF-36), Female Sexual Function Index (FSFI) and Mell-Krat Scale (SFK-K) evaluating QoL and sexuality was used as the research tool. RESULTS: QoL indices for women using EE 30 microg/drsp 3 mg scored higher than for the controls and statistically significantly so with regard to improved general health and mood (p < 0.02), and mental health (p < 0.01). Women taking EE 30 microg/drsp 3 mg functioned sexually better, particularly with regard to sexual arousal (p < 0.006). Using the SFK-K scale, sexual dysfunctions were diagnosed in 66.2% of the women in the control group and 48.3% of those in the EE 30 microg/drsp 3 mg group (p < 0.05). CONCLUSIONS: The intake of the COC containing 30 microg ethinyloestradiol and 3 mg drospirenone is associated with an improvement of general QoL and female sexual functioning. However, the limitations of this study should be taken into account.
    [Abstract] [Full Text] [Related] [New Search]